SCHEMBL13694243

SCHEMBL13694243

O=C(Cc1ccccn1)Nc1ncc([N+](=O)[O-])s1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.62
KMT2A Q03164 9/20 0.62
RAB9A P51151 8/20 0.62
MAPT P10636 7/20 0.62
LMNA P02545 7/20 0.62
NPC1 O15118 6/20 0.62
ALDH1A1 P00352 6/20 0.62
SMN1; SMN2 Q16637 4/20 0.62
HTT P42858 4/20 0.62
ALPL P05186 2/20 0.58
CASP7 P55210 2/20 0.58
CASP6 P55212 2/20 0.58
NSD2 O96028 1/20 0.58
ALPI P09923 1/20 0.58
ALPG P10696 1/20 0.58
CASP8 Q14790 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
NSUN3 Q9H649 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13694246 0.84 MEN1 (0.77) MEN1KMT2ARAB9AMAPTLMNA
SCHEMBL13694244 0.80 NSUN3 (0.78) MEN1KMT2ARAB9AMAPTLMNA
SCHEMBL3914581 0.80 ATG4B (0.72) MEN1KMT2ARAB9AMAPTLMNA
SCHEMBL7067199 0.77 ALPL (0.85) MEN1KMT2ARAB9AMAPTLMNA
SCHEMBL18529266 0.77 RAB9A (1.00) MEN1KMT2ARAB9AMAPTLMNA
SCHEMBL18424530 0.76 ATG4B (0.69) MEN1KMT2ARAB9AMAPTLMNA
SCHEMBL881339 0.76 LMNA (0.84) MEN1KMT2ARAB9AMAPTLMNA
SCHEMBL3466003 0.76 LMNA (0.67) MEN1KMT2ARAB9AMAPTLMNA
SCHEMBL1394449 0.75 RAB9A (0.75) MEN1KMT2ARAB9AMAPTLMNA
SCHEMBL5602524 0.75 RAB9A (0.58) MEN1KMT2ARAB9AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221647-A1 N-(2-THIAZOLYL)-AMIDE DERIVATIVES AS GSK-3 INHIBITORS NOSCIRA, S.A. (ES) 2009-09-03 US disclosed
US-20090221647-A1 N-(2-THIAZOLYL)-AMIDE DERIVATIVES AS GSK-3 INHIBITORS NOSCIRA, S.A. (ES) 2009-09-03 US disclosed
WO-2007125110-A1 N- ( 2-THIAZOLYL) -AMIDE DERIVATIVES AS GSK-3 INHIBITORS NOSCIRA, S.A. (ES) 2007-11-08 WO disclosed
EP-1849785-A1 N-(2-Thiazolyl)-amide derivatives as GSK-3 inhibitors Neuropharma, S.A. (ES) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221647-A1 N-(2-THIAZOLYL)-AMIDE DERIVATIVES AS GSK-3 INHIBITORS GSK3B, GSK3A, GSKIP MEN1 2935/4885KMT2A 1631/4885RAB9A 3781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.